The Oxford/AstraZeneca vaccine is less effective against the South Africa variant of COVID-19, researchers have found.
The researchers who developed the jab say it offers only limited protection against mild disease caused by the novel variant E484K.
However, early data also shows that the jab can prospectively protect against more severe disease caused by the mutation.